Cansativa Group is a German company that serves as a central platform for the distribution and management of medical cannabis products in the country. Established in 2017, the company has built a business-to-business platform that enables customers to handle every stage of the cannabis value chain, from importing goods to distributing them to thousands of pharmacies across Germany.
Cansativa Group holds an exclusive relationship with the Federal Institute for Drugs and Medical Devices (BfArM), making it the only company authorized to distribute domestically-grown medical cannabis in Germany. The company aims to simplify cannabis commerce by ensuring product availability and offering ancillary solutions, positioning itself as Europe's one-stop-shop for all cannabis-related products and services.
In February 2022, Cansativa Group secured USD 15 million in a Series B funding round led by Casa Verde, a prominent cannabis venture capital firm. The investment enabled the company to expand its medical cannabis product portfolio and prepare for the upcoming legalization of recreational cannabis in Germany.
Cansativa Group has acquired a reputation as Germany's largest medical cannabis distributor and a driving force in the country's rapidly evolving cannabis industry. As Germany moves toward legalizing adult-use cannabis, the company is strategically positioned to become the operating backbone for cannabis retail, playing a vital role in enabling access to cannabis for all.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.